openPR Logo
Press release

Global LAG 3 Inhibitor Clinical Trials and Market Opportunity Insight 2028

05-19-2022 05:41 PM CET | Health & Medicine

Press release from: Kuick Resarch

Global LAG 3 Inhibitor Clinical Trials and Market Opportunity

Global LAG 3 Inhibitor Clinical Trials and Market Opportunity Insight 2028 Report Highlights:

* Global LAG 3 Inhibitors Market Dynamics
* Clinical Approaches to Target LAG 3 Inhibitors
* Number of LAG 3 Inhibitors Drug In Trials
* LAG 3 Inhibitors Approved Patent Insight
* LAG 3 Inhibitors Trials By Phase, Company, Country, Indication
* Company Agreement/Partnership/Deals For Ongoing Trials
* LAG-3 Targeted Approach in Cancer Therapy
* Therapeutic Approaches for Novel LAG-3 Targeted Therapy
* Global LAG 3 Inhibitor Market Future Outlook

Download Report: https://www.kuickresearch.com/report-lag3-lag-3-inhibitors-clinical-trials-inhibitor-research-market-cd233-immunotherapy

Cancer immunotherapy is a novel approach which can reverse tumor immune escape by suppressing immune checkpoint pathways. Several immune checkpoint inhibitors targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have demonstrated durable efficacy against melanoma, renal, lung and other cancers. However, despite these promising long-term responses, the majority of patients failed to respond to immune checkpoint blockade, demonstrating primary resistance. Additionally, many of these patients who initially respond to treatment eventually experience relapse secondary to acquired resistance.

To mitigate these challenges, researchers have identified several co-stimulatory receptors including lymphocyte activation gene-3 (LAG-3). LAG-3 is a member of the immunoglobulin superfamily (IgSF) and exerts a wide variety of biologic impacts on T cell function. It is expressed on the cell membranes of natural killer (NK) cells, tumor infiltrating lymphocytes (TIL), a subset of T cells, and dendritic cells. Beyond its role in wide range of autoimmune diseases, it also reduces the body's ability to resist infection and promote chronic infections. Apart from this, the receptor is also over-expressed in several cancers including breast cancer, melanoma, non-Hodgkin lymphoma, myeloma, gastric cancer, and others.

The receptor is considered as a promising target in cancer immunotherapy. Studies have demonstrated that LAG-3 has synergistic action with PD-1 and PD-L1. Although the exact mechanism is unclear, it is shown that its modulation causes a negative regulatory effect over T cell function, preventing tissue damage, and autoimmunity. LAG-3 and PD-1 are frequently co-expressed and upregulated on tumor-infiltrating lymphocytes (TILs) leading to immune exhaustion and tumor growth. The blocking of LAG-3 not nly improves anti-tumor immune responses but also potentiates other forms of immunotherapy given its different mechanism of action mainly mediated by impeding cell cycle progression.

At present, researchers have developed two inhibitory approaches including LAG-3 Ig fusion proteins (IMP321) and LAG-3 targeting antibodies. IMP321 developed by Immutep is a soluble forms of LAG-3 which upregulates co-stimulatory molecules and increases interleukin (IL)-12 productions to enhance tumor immune responses. Several LAG-3 targeting monoclonal antibodies have been developed which interferes with the LAG-3 interaction between major histocompatibility complex-II molecules expressed by tumor or immune cells, promoting tumor cell apoptosis. To further enhance the efficacy of LAG-3 targeting drugs, researchers have also established several bispecific antibodies which have enhanced efficacy, specificity, and are cost effective.

There are more than 100 ongoing clinical trials for 35 drugs, which are evaluating the role of LAG-3 inhibitors in wide range of cancers. Relatlimab developed by Bristol Myers Squibb is one of promising LAG-3 targeting antibody which was granted priority review by US FDA for the management of melanoma in combination with Nivolumab. The drug is expected to gain entry in market by 2022, which will revolutionize the paradigm of cancer treatment. Apart from this, several preclinical studies are also evaluating the role of LAG-3 in other therapeutic indications including diabetes, multiple sclerosis, HIV, Parkinson, and other autoimmune disorders.

The emerging trend in LAG-3 next generation immunotherapies with continuous headway movement along with new emerging technologies for the development of target therapies argues the hope for better alternative therapies during the forecast period. The growing burden of critical diseases such as cancer, leukemia, lymphoma, and muscular degeneration are the major factors that boost the adoption of LAG3 targeting drugs among the global population. Moreover, rise in number of pipeline drugs and high growth potential in untapped emerging economies is expected to open new opportunities for the market players in future. The key players in the market include MacroGenics, Zai Lab, Bristol-Myers Squibb, Ono Pharmaceuticals, Immutep, Novartis, Merck, F-star Therapeutics, among others.

Contact:

Neeraj Chawla
Research Head
Kuick Research
neeraj@kuickresearch.com
+919810410366
https://www.kuickresearch.com/

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global LAG 3 Inhibitor Clinical Trials and Market Opportunity Insight 2028 here

News-ID: 2629974 • Views: 110

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for LAG

Lag Bolts Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Lag Bolts market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global Lag Boltsmarket by key players, product type, applications and regions,etc. The main objective of this market research is to help the readers understand the structure of Lag Boltsmarket, market definition, overview, industry opportunities and trends, investment
Jet Lag Treatment Market Pin-point Analyses of Market Competition Dynamics
Jet lag is a physiological disorder that occurs when the human body gets shifted into a new time zone. This term is commonly used to address all the problems encountered by travelers while flying across several time zones. This disorder is called a "jet" lag as it merely occurs following a rapid air travel. Majority of symptoms of jet lag occurs largely due to the changed or disrupted sleep schedule
Jet Lag Therapy Market : Current Trends & Opportunities by 2025
Jet lag is a group of various symptoms shown by physiologic alterations that occur when the body is shifted into a new time zone. Travel tiredness and exhaustion is a more complex addition of various physiologic, psychological, and environmental factors that arise during an individual trip, collecting over the course of a season. Jet lag has been observed in pilots, air travelers, cabin crew members, physicians, and athletes. The effect
Jet Lag Therapy Market to Witness Exponential Growth by 2025
Jet lag is a group of various symptoms shown by physiologic alterations that occur when the body is shifted into a new time zone. Travel tiredness and exhaustion is a more complex addition of various physiologic, psychological, and environmental factors that arise during an individual trip, collecting over the course of a season. Jet lag has been observed in pilots, air travelers, cabin crew members, physicians, and athletes. The effect
Jet Lag Treatment Market to Undertake Strapping Growth During 2017 - 2025
Jet lag is a physiological disorder that occurs when the human body gets shifted into a new time zone. This term is commonly used to address all the problems encountered by travelers while flying across several time zones. This disorder is called a “jet” lag as it merely occurs following a rapid air travel. Majority of symptoms of jet lag occurs largely due to the changed or disrupted sleep schedule
Recent Study Reveals Growth Prospects of Jet Lag Therapy Market During 2017 - 20 …
Jet lag is a group of various symptoms shown by physiologic alterations that occur when the body is shifted into a new time zone. Travel tiredness and exhaustion is a more complex addition of various physiologic, psychological, and environmental factors that arise during an individual trip, collecting over the course of a season. Jet lag has been observed in pilots, air travelers, cabin crew members, physicians, and athletes. The effect